Navigation Links
Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
Date:7/22/2008

Report Includes an Individual's Genetic Risk Based on Clinical Data,

Preventive Measure Guidance and Scientific Educational Materials

WALTHAM, Mass., July 22 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), today announced the launch of an enhanced test report format and information package for the company's Heart Health Genetic Test. The test is currently marketed under the brand name Gensona(R) Heart Health Genetic Test by Quixtar/Amway. The new report will include quantified risk information on heart attack and coronary artery disease generated from clinical studies and conducted by the company. The company believes that this enhanced report format will provide individuals and their physicians more complete information about a person's inflammation-based genetic risk factor for a heart attack. The new package also provides information on the science behind the genetic test and information to help people understand preventive measures and actions that can be taken to lower the risk of heart disease.

In addition, the company will conduct scientific lectures on the Gensona(R) test for interested Quixtar/Amway individual business owners at their scheduled conferences. The first of these lectures will be on Saturday morning and afternoon, July 26, 2008 at the Nardone/Melillo/Callendar conference at the Radisson Valley Forge Hotel & Convention Center in Valley Forge, PA. Thousands of attendees are expected at the conference.

Lewis H. Bender, Chief Executive Officer at Interleukin Genetics, commented, "Heart disease is by far the leading killer of Americans. Individuals with different interleukin gene variations have vastly different clinical trajectories for heart disease progression. The ability
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
2. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
3. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
4. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
5. New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer
6. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
7. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
8. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
9. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
10. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
11. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...., Sept. 5 /PRNewswire-USNewswire/ -- A team of,re...at U.S. immigrants from,India and Pakistan take on...heir risks of prostate cancer among male immigrant...r and prostate cancer develop due to many reasons,...jor role in these cancers,",said Jame Abraham, M.D...
(Date:9/4/2008)... in TaqMan(R) real-time PCR testing for the diagno...NTON, Calif., Sept. 4 /- The U.S. Foo...he COBAS(R) TaqMan(R) HBV Test,the first assay fo...he U.S.,The test uses Roche,s real-time PCR techno...NA in a patient,s blood. Doctors may use viral loa...
(Date:9/4/2008)...and, September 4 /- Axentis Pharma AG...s the safety and tolerability,of a new therapeutic...,infection in cystic fibrosis patients. The new fo...to be delivered directly to the site of,infection....ts of two,different doses of the new drug. Initial...
(Date:9/3/2008)...a, Sept. 4 /Xinhua--,Pharma...) today announced,that it has enrolled the first s...ial evaluating Bronchitol in cystic fibrosis suffe... hospitals across North,America, Argentina and Ger...xis seeks approval to market Bronchitol for cystic...
Breaking Medicine Technology:Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 2Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 3Body Image is a Concern for Students of All Ages 23875 1Body Image is a Concern for Students of All Ages 23875 2Transportation Company Angel MedFlight Worldwide Air Ambulance Services Signs Contract with Blue Cross Blue Shield 23871 1Transportation Company Angel MedFlight Worldwide Air Ambulance Services Signs Contract with Blue Cross Blue Shield 23871 2Noesis Health Introduces AdvancedSMAT for Better Management of Cloverleaf Message Files 23867 1Noesis Health Introduces AdvancedSMAT for Better Management of Cloverleaf Message Files 23867 2Dr Richard M Soll Joined WuXi PharmaTech 28NYSE 3A WX 29 as VP of Medicinal Chemistry 23865 1Dr Richard M Soll Joined WuXi PharmaTech 28NYSE 3A WX 29 as VP of Medicinal Chemistry 23865 2
... II GBM study presented at ASCO with cediranib - a... quarter of patients alive,and progression- free a...e/ -- Data for the,investigational agent cediranib...ing of the American Society of Clinical Oncology,(...blastoma (GBM),an invasive form of brain tumor wi...
...itive data on subcutaneous administration show pot...atients -, CHICAGO, June 04, 2007 /PRNewswire-Firs...nnounced the presentation of positive,data for VEL...,multiple myeloma (MM) who have received at least ... a Phase II trial for subcutaneous,(SC) administra...
Other Medicine Technology:Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 7
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...responsible for checking the profits and safety of... to the NHS. They have to monitor that only brande...ould be reasonable. The Pharmaceutical Price Regu...nization which monitors and legislates the agreeme...
...ve come up with a disaster-planning guide to help ...nted by tropical storms, hurricanes, tidal waves a...world, people are vulnerable to some sort of natur...ke, flood, hurricane, or tornado. In addition, ter...
...ed over the increasing malfunction of heart device... deaths between 1990 and 2002. The Food and Drug A...ng with physicians and heart-device manufacturers ...llators had failed between 2000 and 2003. Same num...
...he damages in the heart from the use of stem cells...s from mice to repair heart damage in sheep, repor...sue of The Lancet. Heart failure is a major cause ...es, occurring when cells within the heart are dama...
Other Medicine News:Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device.
Clinicians are demanding smaller, higher performing systems specifically designed to meet their clinical and operational challenges. The new Philips HD11 XE system provides a powerful architecture fo
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea
InfinixTM CF-i/SP brings revolutionary flexibility to floor-mounted X-ray systems. The unique design enables operators to move the C-arm around the exam table as needed to obtain the optimal angle fo
Medicine Products: